| Name | Title | Contact Details |
|---|
Touchstone partners with individuals, families, schools and other service providers to deliver the optimal continuum of health, education, social services
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Unlocking the health benefits of cannabinoids. Learn More Unlocking the health benefits on cannabinoidsLearn more We are a team of medical experts. Meet our team https://sanitygroup.com/wp-content/uploads/2020/11/SP_Homepage_Video_Compressed_BW.mp4 Med...
Sauflon Pharmaceuticals is a Hicksville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alpharma, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.